Spectroscopic method for measuring activity of cis-aconitate decarboxylase, an important metabolic regulator of immune responses
- PMID: 40653293
- PMCID: PMC12323396
- DOI: 10.1016/j.ab.2025.115944
Spectroscopic method for measuring activity of cis-aconitate decarboxylase, an important metabolic regulator of immune responses
Abstract
Cis-aconitate decarboxylase (ACOD1) is a key enzyme converting cis-aconitate to itaconate, which has therapeutic potential for inflammatory diseases. Existing methods to measure ACOD1 activity and itaconate are often expensive and complex. We developed a novel, high-throughput spectrophotometric assay using the Fürth-Herrmann reaction. Our method quantifies ACOD1-catalyzed itaconate production by leveraging distinct absorbance ratios of cis-aconitate and itaconate at 386 nm and 440 nm. We optimized parameters, characterized human ACOD1 kinetics, and determined an IC50 for citraconate consistent with previous reports. This simple, fast, and reliable assay, requiring only a UV-Vis spectrophotometer, will accelerate screening for ACOD1 modulators, speeding up therapeutic development.
Keywords: Immune-Responsive Gene 1 (IRG1); Itaconate; Spectrophotometry; cis-aconitate decarboxylase (ACOD1).
Copyright © 2025. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Itaconate and obesity-related hormones promote tumor progression - new insights on metabolic dysfunction in early-onset colon cancer.Front Immunol. 2025 Jun 9;16:1572985. doi: 10.3389/fimmu.2025.1572985. eCollection 2025. Front Immunol. 2025. PMID: 40552282 Free PMC article.
-
Hyperglycemia-Suppressed Acod1 Expression Contributes to Innate Immune Deficiency in Pseudomonas aeruginosa Keratitis.Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):51. doi: 10.1167/iovs.66.9.51. Invest Ophthalmol Vis Sci. 2025. PMID: 40673739 Free PMC article.
-
Itaconate: A key regulator of immune responses and potential therapeutic target for autoimmune and inflammatory diseases.Autoimmun Rev. 2025 Jul 17;24(10):103885. doi: 10.1016/j.autrev.2025.103885. Online ahead of print. Autoimmun Rev. 2025. PMID: 40683614 Review.
-
Suppression of HIV-TAT and cocaine-induced neurotoxicity and inflammation by cell penetrable itaconate esters.J Neurovirol. 2024 Aug;30(4):337-352. doi: 10.1007/s13365-024-01216-9. Epub 2024 Jun 17. J Neurovirol. 2024. PMID: 38884890 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
-
- Qian C, Wang Y, Yuan Q, Guo Y, Wang Y, Insights into the itaconate family: Immunomodulatory mechanisms and therapeutic potentials, Eur J Pharmacol, 997 (2025) 177542. - PubMed
-
- Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, Cervantes-Barragan L, Ma X, Huang SC, Griss T, Weinheimer CJ, Khader S, Randolph GJ, Pearce EJ, Jones RG, Diwan A, Diamond MS, Artyomov MN, Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation, Cell Metab, 24 (2016) 158–166. - PMC - PubMed
-
- Sakai A, Kusumoto A, Kiso Y, Furuya E, Itaconate reduces visceral fat by inhibiting fructose 2,6-bisphosphate synthesis in rat liver, Nutrition, 20 (2004) 997–1002. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources